Table 3.
Individual treatment utilization rates by clinical groups in 2019
| Variables (%) | Overall | ASCVD | Commercial | |||
|---|---|---|---|---|---|---|
| CKD | HF | Hypo | Obesity | |||
| Metformin | 85.3 | 80.3 | 74.1 | 71.5 | 60.4 | 84.5 |
| SU | 26.5 | 27.3 | 32.0 | 27.0 | 25.3 | 25.7 |
| SGLT-2i | 21.1 | 23.1 | 22.0 | 20.3 | 19.0 | 21.9 |
| GLP-1 RA | 20.8 | 23.0 | 26.5 | 22.8 | 25.0 | 24.5 |
| DPP-4 | 18.0 | 19.1 | 20.5 | 17.7 | 16.7 | 17.2 |
| Basal insulin | 12.0 | 14.6 | 18.0 | 17.2 | 21.9 | 12.4 |
| Bolus insulin | 8.5 | 13.3 | 17.1 | 19.1 | 36.0 | 9.5 |
| TZD | 6.7 | 6.4 | 8.4 | 5.0 | 7.4 | 6.7 |
| Pre-mixed insulin | 1.4 | 2.0 | 2.7 | 2.7 | 5.2 | 1.5 |
| Insulin/GLP-1 RA | 0.9 | 1.0 | 1.3 | 1.1 | 1.4 | 1.0 |
| Variables (%) | Overall | ASCVD | Medicare | |||
|---|---|---|---|---|---|---|
| CKD | HF | Hypo | Obesity | |||
| Metformin | 74.5 | 69.8 | 60.7 | 58.2 | 43.0 | 72.4 |
| SU | 31.8 | 32.1 | 35.4 | 32.7 | 28.6 | 31.3 |
| DPP-4 | 21.5 | 22.1 | 23.5 | 21.6 | 19.1 | 20.8 |
| Basal insulin | 12.9 | 14.2 | 16.5 | 16.5 | 22.3 | 14.4 |
| GLP-1 RA | 11.6 | 11.7 | 12.6 | 10.8 | 11.3 | 14.6 |
| SGLT-2i | 10.5 | 10.4 | 8.5 | 8.1 | 6.9 | 11.3 |
| Bolus insulin | 10.2 | 12.3 | 15.3 | 17.4 | 34.2 | 12.4 |
| TZD | 6.8 | 6.3 | 7.4 | 5.1 | 6.7 | 7.0 |
| Pre-mixed insulin | 2.0 | 2.4 | 3.0 | 3.4 | 6.5 | 2.5 |
| Meglitinides | 1.9 | 2.2 | 2.6 | 2.6 | 2.7 | 1.8 |
ASCVD atherosclerotic cardiovascular disease; CKD chronic kidney disease; DPP-4 dipeptidyl peptidase-4 inhibitor; GLP-1 RA glucagon-like peptide-1 receptor agonist; HF heart failure; Hypo hypoglycemia; SGLT-2i sodium-glucose co-transporter 2 inhibitor; SU sulfonylurea; TZD thiazolidinedione